Ginette Serrero

Dr. Ginette Serrero

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
GSGinette Serrero
Ginette Serrero
DHDouglas M Hawkins
Douglas M Hawkins
BYBinbin Yue
Binbin Yue
OIOlga Ioffe
Olga Ioffe
PBPablo Bejarano
Pablo Bejarano
WKWes E Kim
Wes E Kim
Introduction: GP88 (progranulin) has been implicated in tumorigenesis and resistance to anti-estrogen therapies for estrogen receptor positive (ER+) breast cancer. Previous pathological studies showed that GP88 is expressed in invasive ductal carcinoma (IDC), but not in normal mammary epithelial tissue, benign lesions or lobular carcinoma. Based on these results, the present study examines GP88 prognostic significance in association with recurrence and death risks for ER+ IDC patients. Methods: Two retrospective multi-site clinical studies examined GP88 expression by immunohistochemistry (IHC) analysis of paraffin-embedded breast tumor tissue sections from ER+ IDC patients (lymph node positive and negative, stage 1 to 3) in correlation with patients' survival outcomes. The training study established a GP88 cut-off value associated with decreased disease-free (DFS) and overall (OS) survivals. The validation study verified the GP88 cut-off value and compared GP88 prognostic information with other prognostic factors, particularly tumor size, grade, disease stage and lymph node status in multivariate analysis. Results: GP88 expression is associated with a statistically significant increase in recurrence risk for ER+ IDC patients. The training study established that GP88 3+ score was associated with decreased DFS (P = 0.0004) and OS (P = 0.0036). The independent validation study verified that GP88 3+ score was associated with a 5.9-fold higher hazard of disease recurrence and a 2.5-fold higher mortality hazard compared to patients with tumor GP88 < 3+. GP88 remained an independent risk predictor after considering age, ethnicity, nodal status, tumor size, tumor grade, disease stage, progesterone receptor expression and treatments. Conclusions: The survival factor GP88 is a novel prognostic biomarker, predictive of recurrence risk and increased mortality for non-metastatic ER+ IDC patients. Of importance, our data show that GP88 continues to be a prognostic factor even after five years. These results also provide evidence that GP88 provides prognostic information independent of tumor and clinical characteristics and would support prospective study to examine whether GP88 expression could help stratify patients with ER+ tumors for adjuvant therapy.

1 September 2014 in Human Pathology
Verified
Journal Article
Closed access
MEMartin J. Edelman
Martin J. Edelman
JFJosephine Feliciano
Josephine Feliciano
BYBinbin Yue
Binbin Yue
PBPablo Bejarano
Pablo Bejarano
OIOlga Ioffe
Olga Ioffe
GSGinette Serrero
Ginette Serrero

9 June 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TATesfom Abrhale
Tesfom Abrhale
ABAngela Brodie
Angela Brodie
GSGauri Sabnis
Gauri Sabnis
LMLuciana Macedo
Luciana Macedo
CTChangsheng Tian
Changsheng Tian
GSGinette Serrero
Ginette Serrero
Background: Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer. However, some patients display de novo or acquired resistance to AI. Interactions between estrogen and growth factor signaling pathways have been identified in estrogen-responsive cells as one possible reason for acquisition of resistance. Our laboratory has characterized an autocrine growth factor overexpressed in invasive ductal carcinoma named PC-Cell Derived Growth Factor (GP88), also known as progranulin. In the present study, we investigated the role GP88 on the acquisition of resistance to letrozole in ER+breast cancer cellsMethods: We used two aromatase overexpressing human breast cancer cell lines MCF-7-CA cells and AC1 cells and their letrozole resistant counterparts as study models. Effect of stimulating or inhibiting GP88 expression on proliferation, anchorage-independent growth, survival and letrozole responsiveness was examined.Results: GP88 induced cell proliferation and conferred letrozole resistance in a time- and dose-dependent fashion. Conversely, naturally letrozole resistant breast cancer cells displayed a 10-fold increase in GP88 expression when compared to letrozole sensitive cells. GP88 overexpression, or exogenous addition blocked the inhibitory effect of letrozole on proliferation, and stimulated survival and soft agar colony formation. In letrozole resistant cells, silencing GP88 by siRNA inhibited cell proliferation and restored their sensitivity to letrozole.Conclusion: Our findings provide information on the role of an alternate growth and survival factor on the acquisition of aromatase inhibitor resistance in ER+breast cancer.

1 January 2011 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
KTKatherine Rak Tkaczuk
Katherine Rak Tkaczuk
BYBinbin Yue
Binbin Yue
MZMin Zhan
Min Zhan
NTNancy Tait
Nancy Tait
LYLavanya Yarlagadda
Lavanya Yarlagadda
GSGinette Serrero
Ginette Serrero
Introduction: GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between breast cancer patients (BC) and healthy volunteers (HV). Methods: An IRB approved prospective study enrolled 189 stage 1–4 BC patients and 18 HV. GP88 serum concentration was determined by immunoassay. Results: Serum GP88 level was 28.7+ 5.8 ng/ml in HV and increased to 40.7+ 16.0 ng/ml ( P= 0.007) for stage 1-3 and 45.3 +23.3 ng/ml ( P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression. Conclusion: These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.

1 June 2003
Verified
Journal Article
Closed access
WWWengang Wang
Wengang Wang
JHJun Hayashi
Jun Hayashi
WKWes E Kim
Wes E Kim
GSGinette Serrero
Ginette Serrero

1 April 2017 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
AKAkio Kimura
Akio Kimura
MTMasao Takemura
Masao Takemura
KSKuniaki Saito
Kuniaki Saito
GSGinette Serrero
Ginette Serrero
NYNobuaki Yoshikura
Nobuaki Yoshikura
TITakashi Inuzuka
Takashi Inuzuka